The USD 37.5m series B financing was led by Sequoia China and LYFE Capital, and supported by existing series A investors, VI Ventures and Nest.Bio Ventures, as well as new investors, Legend Star Capital and Proxima Ventures.
HiFiBiO Therapeutics currently has more than 50 full-time employees operating out of three facilities in the US, France, and China. Both the laboratories in Cambridge, Mass. and Hangzhou, China are located within the Nest.Bio Ventures incubator facilities.
The company continues to establish multiple strategic partnerships with leading pharmaceutical and biotechnology companies to drive an innovative pipeline of antibody drugs that leverage its proprietary single-B-cell functional antibody discovery CelliGOTM platform.
HiFiBiO Therapeutics is mobilizing the human immune system to combat disease.
The company integrates deep-rooted biological expertise with comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment
Cellipont Bioservices and Ernexa Therapeutics form cell therapy partnership
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
CStone announces Phase I CS2009 data at ESMO 2025
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
Bristol Myers Squibb to acquire Orbital Therapeutics for USD1.5bn to expand cell therapy portfolio
Celltrion launches AVTOZMA IV in the United States following FDA approval
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
EMA recommends marketing approval of Alvotech's Gobivaz biosimilar to Simponi